Use of cangrelor for complex percutaneous coronary intervention in the context of concomitant severe aortic stenosis:

Francesco Soriano1, Andrea R Munafò1, Nurcan Baydaroglu1

  • 1Interventional Cardiology, De Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.

Summary

Cangrelor, a P2Y12 inhibitor, can minimize bleeding and thrombotic risks during transcatheter aortic valve implantation (TAVI) with percutaneous coronary intervention (PCI). This approach offers tailored platelet inhibition for complex procedures.